1. AFMPS (2018) Switch et substitution des médicaments biologiques. https://www.afmps.be/fr/switch_et_substitution_des_medicaments_biologiques
2. AkdÄ (2021) Leitfaden „Biosimilars“ der Arzneimittelkommission der deutschen Ärzteschaft. 2. Auflage, Version 1.0. www.akdae.de/fileadmin/user_upload/akdae/Arzneimitteltherapie/LF/PDF/Biosimilars.pdf
3. Allocati E, Godman B, Gobbi M, Garattini S, Banzi R (2022) Switching among biosimilars: a review of clinical evidence. Front Pharmacol 13:917814
4. AMELI (2022) La Rémunération sur objectifs de santé publique en 2021. https://assurance-maladie.ameli.fr/sites/default/files/2022-04-26-CP-Rosp-2021.pdf
5. Authority for Consumers and Markets (2022) Drug manufacturer Pfizer to discontinue its steering pricing structure for Enbrel following discussions with ACM. https://www.acm.nl/en/publications/drug-manufacturer-pfizer-discontinue-its-steering-pricing-structure-enbrel-following-discussions-acm?utm_source=POLITICO.EU&utm_campaign=5ded7c77d7-EMAIL_CAMPAIGN_2022_02_14_06_00&utm_medium=email&utm_term=0_10959edeb5-5ded7c77d7-190517957